Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|||||
| License revenue | $ 0 | $ 800 | $ 3,500 | $ 7,962 | ||||||
| Operating expenses: | ||||||||||
| Research and development | 5,654 | $ 4,476 | 9,693 | $ 24,465 | 32,109 | 21,926 | ||||
| General and administrative | 1,705 | 1,909 | 4,460 | 4,357 | 8,391 | 7,961 | ||||
| Total operating expenses | 7,359 | 6,385 | 14,153 | 28,822 | 40,500 | 29,887 | ||||
| Loss from operations | (7,359) | (6,385) | (13,353) | (28,822) | (37,000) | (21,925) | ||||
| Other income (expense): | ||||||||||
| Interest income | (194) | 298 | (313) | 298 | 374 | 1,194 | ||||
| Other income (expense), net | (32) | (172) | 4 | (49) | 71 | (137) | ||||
| Total other income, net | (226) | 126 | (309) | 249 | 445 | 1,057 | ||||
| Provision for income taxes | 0 | 0 | (13) | (280) | ||||||
| Loss before income taxes | (7,585) | (6,259) | (13,662) | (28,573) | (36,555) | (20,868) | ||||
| Net loss | (7,585) | (6,259) | (13,662) | (28,573) | (36,568) | (21,148) | ||||
| Accretion of redeemable convertible preferred shares | 3,149 | 2,908 | 6,200 | 5,759 | 11,816 | 10,890 | ||||
| Net loss attributable to ordinary shareholders | $ (10,734) | $ (9,167) | $ (19,862) | $ (34,332) | $ (48,384) | $ (32,038) | ||||
| Loss per share ordinary share — basic and diluted | ||||||||||
| Net loss per share, basic | $ (4.46) | $ (4.64) | $ (8.26) | $ (17.38) | $ (22.1) | [1] | $ 16.23 | [1] | ||
| Net loss per share, diluted | $ (4.46) | $ (4.64) | $ (8.26) | $ (17.38) | $ (22.1) | [1] | $ 16.23 | [1] | ||
| Weighted average shares basic and diluted loss per share. | ||||||||||
| Weighted-average common shares outstanding, basic | 1,411,649 | 980,803 | 1,410,811 | 980,803 | 1,194,172 | [1] | 979,098 | [1] | ||
| Weighted-average common shares outstanding, diluted | 1,411,649 | 980,803 | 1,410,811 | 980,803 | 1,194,172 | [1] | 979,098 | [1] | ||
| Comprehensive loss | ||||||||||
| Net loss | $ (7,585) | $ (6,259) | $ (13,662) | $ (28,573) | $ (36,568) | $ (21,148) | ||||
| Other comprehensive income (loss): | ||||||||||
| Foreign currency translation adjustment | (17) | (62) | (26) | (100) | (38) | (136) | ||||
| Total comprehensive loss | $ (7,602) | $ (6,321) | $ (13,688) | $ (28,673) | $ (36,606) | $ (21,284) | ||||
| Series A Preferred Stock | ||||||||||
| Loss per share ordinary share — basic and diluted | ||||||||||
| Net loss per share, basic | $ (4.46) | $ (4.64) | $ (8.26) | $ (17.38) | $ (22.1) | [1] | $ 16.23 | [1] | ||
| Net loss per share, diluted | $ (4.46) | $ (4.64) | $ (8.26) | $ (17.38) | $ (22.1) | [1] | $ 16.23 | [1] | ||
| Weighted average shares basic and diluted loss per share. | ||||||||||
| Weighted-average common shares outstanding, basic | 994,869 | 994,869 | 994,869 | 994,869 | 994,869 | [1] | 994,869 | [1] | ||
| Weighted-average common shares outstanding, diluted | 994,869 | 994,869 | 994,869 | 994,869 | 994,869 | [1] | 994,869 | [1] | ||
| IKENA ONCOLOGY INC | ||||||||||
| Operating expenses: | ||||||||||
| Research and development | $ 4,025 | $ 9,832 | $ 7,740 | $ 19,477 | $ 30,875 | $ 59,652 | ||||
| General and administrative | 4,416 | 5,308 | 10,060 | 11,307 | 23,679 | 24,925 | ||||
| Restructuring and other charges | 309 | 683 | 1,744 | 3,265 | 4,419 | 0 | ||||
| Total operating expenses | 8,750 | 15,823 | 19,544 | 34,049 | 58,973 | 84,577 | ||||
| Loss from operations | (8,750) | (15,823) | (19,544) | (34,049) | (58,973) | (75,417) | ||||
| Collaboration revenue | 0 | 9,160 | ||||||||
| Other income (expense): | ||||||||||
| Investment income | 1,290 | 1,920 | 2,708 | 4,034 | 7,373 | 7,111 | ||||
| Other income (expense), net | 4,708 | 235 | 5,493 | 228 | 2,518 | (22) | ||||
| Total other income, net | 5,998 | 2,155 | 8,201 | 4,262 | 9,891 | 7,089 | ||||
| Provision for income taxes | (15) | (62) | (43) | (89) | (152) | 162 | ||||
| Loss before income taxes | (2,752) | (13,668) | (11,343) | (29,787) | (49,082) | (68,328) | ||||
| Net loss | $ (2,767) | $ (13,730) | $ (11,386) | $ (29,876) | $ (49,234) | $ (68,166) | ||||
| Loss per share ordinary share — basic and diluted | ||||||||||
| Net loss per share, basic | $ (0.69) | $ (3.41) | $ (2.83) | $ (7.43) | $ (12.24) | $ (19.6) | ||||
| Net loss per share, diluted | $ (0.69) | $ (3.41) | $ (2.83) | $ (7.43) | $ (12.24) | $ (19.6) | ||||
| Weighted average shares basic and diluted loss per share. | ||||||||||
| Weighted-average common shares outstanding, basic | 4,021,458 | 4,021,458 | 4,021,458 | 4,021,458 | 4,021,458 | 3,477,923 | ||||
| Weighted-average common shares outstanding, diluted | 4,021,458 | 4,021,458 | 4,021,458 | 4,021,458 | 4,021,458 | 3,477,923 | ||||
| Comprehensive loss | ||||||||||
| Net loss | $ (2,767) | $ (13,730) | $ (11,386) | $ (29,876) | $ (49,234) | $ (68,166) | ||||
| Other comprehensive income (loss): | ||||||||||
| Unrealized gain on marketable securities | (34) | (37) | (3) | (302) | 116 | 715 | ||||
| Total comprehensive loss | $ (2,801) | $ (13,767) | $ (11,389) | $ (30,178) | $ (49,118) | $ (67,451) | ||||
| ||||||||||
| X | ||||||||||
- Definition Accretion of redeemable convertible preferred shares. No definition available.
|
| X | ||||||||||
- Definition Weighted average shares basic and diluted loss per share. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as operating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|